|
Gadolinium Review P&T
FDA Public Health Advisor 12/2006
FDA Public Health Advisory 6/2006 update 12/2006
ACR Guidance Document for Safe MR Practices: 2007
Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should be
Concerned, AJR 2007;586-92
Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis Radiology
3/2007
Gadolinium deposition in nephrogenic fibrosing dermopathy J AM Acad Dermatol
11/2006
Morbidity and Mortality Weekly Report 2/23/2007
Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide
10/2006
Nephrogenic systemic fibrosis following the administration of extracellular
gadolinium based contrast agents: is the stability of the contrast agent
molecule an important factor in the pathogenesis of this condition Br J
Radiology 2007; 73-76
|
0.2 |
ml/kg |
Multihance |
|
|
|
|
|
|
|
|
|
|
|
|
Creatinine Clearnace
(ml/min) |
120 |
110 |
100 |
90 |
80 |
70 |
60 |
50 |
40 |
30 |
20 |
10 |
0 |
|
Half-Life (Hours) |
1.39 |
1.51 |
1.65 |
1.83 |
2.05 |
2.32 |
2.68 |
3.18 |
3.90 |
5.05 |
7.15 |
12.23 |
42.40 |
|
AUC (mg*min/ml) |
56 |
61 |
67 |
74 |
83 |
94 |
109 |
129 |
158 |
205 |
290 |
496 |
1719 |
|
Fractional Dose Needed
to Achieve Same AUC as patient with normal renal function |
1.00 |
0.92 |
0.84 |
0.76 |
0.68 |
0.60 |
0.52 |
0.44 |
0.36 |
0.27 |
0.19 |
0.11 |
0.03 |
|